The current standard treatment of inoperable intrahepatic cholangiocarcinoma (bile duct
cancer in the liver) is chemotherapy, which is of limited efficacy. The use of selective
internal radiotherapy treatment (SIRT-Y90) is proven efficacious in patients with
intra-heptic tumor. Previous experience with SIRT is safe in patients with intrahepatic
cholangiocarcinoma. This study aims to study the benefits of sequential administration of
SIRT followed by standard chemotherapy for treatment of inoperable intrahepatic
cholangiocarcinoma.